Sandra von Meier

Head of Business Development at Desitin Arzneimittel GmbH

Speaker

Sandra is the Head of Business Development at Desitin, a German privately owned company with a market presence in neurology and rare diseases. At Desitin, Sandra is looking to grow the pipeline via licensing and/or acquisition in CNS as well as rare diseases. Previously Sandra was Head of Business Development at Debiopharm, Switzerland, responsible for all business development and licensing activities at Debiopharm, covering both in licensing and out licensing activities with a focus on oncology assets, rare diseases and anti-infectives.

Before joining Debiopharm, Sandra was working as Senior Director Business Development & Licensing at Bayer responsible for oncology asset search, evaluation and transaction including the M&A with Vividion Therapeutics. Before Bayer, as Director Business Development Oncology at Merck KGaA, Sandra led numerous transactions, including the strategic collaboration for Xevinapant, deals with F-star for bispecific antibodies, Vertex for their DDR portfolio and Pfizer for Bavencio/avelumab. Sandra started her career at Medigene, a publicly listed German biotechnology company, where she also closed several transactions including the commercialization agreement with Astellas for Eligard.

Sandra studied Biochemistry at the FU Berlin and then moved to London for her Diploma at the Institute of Cancer Research. She holds a PhD from University College London.